Antioxidant treatment protects against matrix metalloproteinase activation and cardiomyocyte injury during acute pulmonary thromboembolism


Autoria(s): Sousa-Santos, Ozelia; Neto-Neves, Evandro M.; Ferraz, Karina C.; Ceron, Carla S.; Rizzi, Elen; Gerlach, Raquel F.; Tanus-Santos, Jose E.
Contribuinte(s)

UNIVERSIDADE DE SÃO PAULO

Data(s)

30/09/2013

30/09/2013

2012

Resumo

Increased reactive oxygen species (ROS) promote matrix metalloproteinase (MMP) activities and may underlie cardiomyocyte injury and the degradation of cardiac troponin I (cTI) during acute pulmonary thromboembolism (APT). We examined whether pretreatment or therapy with tempol (a ROS scavenger) prevents MMP activation and cardiomyocyte injury of APT. Anesthetized sheep received tempol infusion (1.0 mg kg(-1) min(-1), i.v.) or saline starting 30 min before or 30 min after APT (autologous blood clots). Control animals received saline. Hemodynamic measurements were performed. MMPs were studied in the right ventricle (RV) by gelatin zymography, fluorimetric activity assay, and in situ zymography. The ROS levels were determined in the RV and cTI were measured in serum samples. APT increased the pulmonary arterial pressure and pulmonary vascular resistance by 146 and 164 %, respectively. Pretreatment or therapy with tempol attenuated these increases. While APT increased RV + dP/dt (max), tempol infusions had no effects. APT increased RV MMP-9 (but not MMP-2) levels. In line with these findings, APT increased RV MMP activities, and this finding was confirmed by in situ zymography. APT increased the RV ROS levels and tempol infusion, before or after APT, and blunted APT-induced increases in MMP-9 levels, MMP activities, in situ MMP activities, and ROS levels in the RV. cTI concentrations increased after APT, and tempol attenuated these increases. RV oxidative stress after APT increases the RV MMP activities, leading to the degradation of sarcomeric proteins, including cTI. Antioxidant treatment may prevent MMP activation and protect against cardiomyocyte injury after APT.

Fundacao de Aparo a Pesquisa do Estado de Sao Paulo (FAPESP)

Fundacao de Aparo a Pesquisa do Estado de Sao Paulo (FAPESP)

Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)

Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)

Coordenadoria de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)

Coordenadoria de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)

Identificador

NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, NEW YORK, v. 385, n. 7, pp. 685-696, JUL, 2012

0028-1298

http://www.producao.usp.br/handle/BDPI/33844

10.1007/s00210-012-0748-9

http://dx.doi.org/10.1007/s00210-012-0748-9

Idioma(s)

eng

Publicador

SPRINGER

NEW YORK

Relação

NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY

Direitos

restrictedAccess

Copyright SPRINGER

Palavras-Chave #ANTIOXIDANT #CARDIOMYOCYTE INJURY #CARDIAC TROPONIN I #MATRIX METALLOPROTEINASES #REACTIVE OXYGEN SPECIES #ISCHEMIA-REPERFUSION INJURY #RIGHT-VENTRICULAR DYSFUNCTION #PERMEABLE RADICAL SCAVENGER #CARDIAC TROPONIN-I #OXIDATIVE STRESS #RENOVASCULAR HYPERTENSION #RISK STRATIFICATION #EMBOLISM #RATS #MATRIX-METALLOPROTEINASE-9 #PHARMACOLOGY & PHARMACY
Tipo

article

original article

publishedVersion